July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Blue light-cytotoxic protection of plasma rich in growth factors (PRGF-Endoret) in retinal pigment epithelium cells
Author Affiliations & Notes
  • Sabino Padilla
    BTI ImasD, Vitoria-Gasteiz, Spain
  • Maria de la Fuente
    BTI ImasD, Vitoria-Gasteiz, Spain
  • Francisco Muruzabal
    BTI ImasD, Vitoria-Gasteiz, Spain
  • Borja de la Sen
    BTI ImasD, Vitoria-Gasteiz, Spain
  • Susana Del Olmo-Aguado
    Instituto Universitario Fernández-Vega, Oviedo, Spain
  • Carlota Suarez-Barrio
    Universidad de Oviedo, Oviedo, Asturias, Spain
  • Jesus Merayo-Lloves
    Instituto Universitario Fernández-Vega, Oviedo, Spain
  • Eduardo Anitua
    BTI ImasD, Vitoria-Gasteiz, Spain
  • Footnotes
    Commercial Relationships   Sabino Padilla, BTI ImasD (E); Maria de la Fuente, BTI ImasD (E); Francisco Muruzabal, BTI ImasD (E); Borja de la Sen, BTI ImasD (E); Susana Del Olmo-Aguado, None; Carlota Suarez-Barrio, None; Jesus Merayo-Lloves, None; Eduardo Anitua, BTI ImasD (E)
  • Footnotes
    Support  BIORETINA - HAZITEK from the Basque Country Government
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1692. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sabino Padilla, Maria de la Fuente, Francisco Muruzabal, Borja de la Sen, Susana Del Olmo-Aguado, Carlota Suarez-Barrio, Jesus Merayo-Lloves, Eduardo Anitua; Blue light-cytotoxic protection of plasma rich in growth factors (PRGF-Endoret) in retinal pigment epithelium cells. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1692. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the protective effect of plasma rich in growth factors (PRGF-Endoret) over blue-light treated retinal pigment epithelium cells cytotoxicity

Methods : Eye drops were obtained using the Endoret (PRGF) Ophthalmology kit (BTI Biotechnology Institute, S.L., Vitoria, Spain). Briefly, after informed consent was obtained, blood from healthy donors was collected into 9 mL tubes. Blood was centrifuged at 580g for 8 minutes, whole plasma column was drawn off avoiding the buffy coat, incubated at 37 oC for one hour, and the released supernatants were collected and filtered. Retinal pigment epithelium (ARPE-19) cells were exposed to blue light (470 nm) for 24 hours. Then, cells were incubated with PRGF or with routine culture medium (control) for another 24 and 48 hours maintaining the exposure to blue light. The cytoprotective effect of PRGF on blue light exposed ARPE-19 cells was evaluated by measuring the cell viability, the ROS production, the mitochondrial health status (JC-10) and the expression of some proteins related to the cellular stress like heme-oxygenase 1 (HO-1), catalase and superoxide dismutase (SOD-1)

Results : The cell viability increased significantly at 24 and 48 hours after PRGF treatment comparing to the control group. The synthesis of ROS was significantly diminished in cells treated with PRGF but very elevated in the case of control. Also, after 24 hours of PRGF treatment, the JC-10 expression that reflects mitochondrial membrane potential was decreased. HO-1 levels measured by immunofluorescence and western blot was significantly reduced after PRGF treatment at both times of treatment. Furthermore, a significant increase of catalase expression was observed after PRGF treatment at 24 and 48 h regarding to the control group. However, no significant changes were observed in SOD-1 expression between both groups

Conclusions : The present results suggest that PRGF treatment exerts cytotoxic protective effects on blue light-oxidative stress in an in vitro model of pigment epithelial cells

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×